Try our Advanced Search for more refined results
Life Sciences
Life Sciences Law360 provides breaking legal news and analysis on the pharmaceutical and medical device industry. Coverage includes high-stakes litigation and policy developments that affect life sciences companies, as well as licensing deals, mergers, and other corporate transactions.
Sign up for a 7-day FREE trial today!
Latest News in Life Sciences
-
March 13, 2026
AIG Policy Excludes $150M Pollution Coverage, 7th Circ. Finds
A Seventh Circuit panel on Friday ruled an AIG unit has no duty to cover $150 million in legal costs for Sterigenics and its former parent company following input from the Illinois Supreme Court on how to apply a pollution exclusion in the relevant policy.
-
March 13, 2026
Maryland Bros. Get Prison For HIV Drug Fraud Scheme
A Florida federal judge on Friday sentenced two Maryland brothers to prison for their roles in a fraudulent medication scheme that involved selling misbranded HIV drugs with fake tracing documents to pharmacies and patients.
-
March 13, 2026
She Has A Point: Finnegan's Cora Holt
Cora Holt, a partner at Finnegan Henderson Farabow Garrett & Dunner LLP in Washington, D.C., has a "do your job" attitude and "getting the stuff done" approach to litigation that earned plaudits from Kassie Helm, co-chair of Dechert LLP, who praised Holt for her work as part of a Law360 series celebrating women litigators.
-
March 13, 2026
Neuropsych Drugmaker Wants Out Of Investors' IPO Data Suit
Neuropsychiatric drugmaker Neumora Therapeutics Inc. seeks to shed investor claims it mischaracterized certain clinical study data ahead of its September 2023 initial public offering, arguing that the trading price decline cited in the complaint was tied to results from a different study that occurred after the IPO.
-
March 13, 2026
4th Circ. Brings Back Allergan Medicaid Overcharging Suit
A split Fourth Circuit panel on Friday revived a whistleblower suit accusing an Allergan Sales LLC predecessor of overcharging Medicaid by more than $680 million, saying the whistleblower plausibly alleged the company knowingly improperly aggregated discounts into "best prices" for drugs.
Areas of Coverage
- AGENCIES
- U.S. Consumer Product Safety Commission
- U.S. Food and Drug Administration
- U.S. Patent and Trademark Office
- U.S. International Trade Commission
- POLICY & REGULATION
- Affordable Care Act
- Federal Food, Drug, and Cosmetic Act
- Antitrust and consumer protection controls
- Drug and medical device lobbying
- State and international life sciences legislation and regulation
- ENFORCEMENT
- Drug and medical device recalls
- Drug safety actions
- Pay-for-delay investigations
- Merger reviews
- LITIGATION
- Patent disputes, including
- Abbreviated New Drug Application litigation
- Section 301 cases
- Product safety suits over drugs and medical devices, including off-label marketing and failure-to-warn claims
- Consumer litigation and class actions
- Fraud and compliance suits
- Antitrust disputes
- Labor and employment suits
- Shareholder and corporate governance disputes
- Bankruptcy proceedings
- TRANSACTIONS
- Mergers, acquisitions, and joint ventures
- Share buybacks and stock splits
- Private equity deals
- Patent-licensing agreements
- PROFILES
- Personnel moves
- Profiles of life sciences practice groups
Readership
- Life sciences lawyers at top law firms
- Corporate counsel and compliance officers at Fortune 1000 companies
- Executives and attorneys in the drug, biotechnology, and medical device industries
- Information experts at law firms, agencies, and companies
- Policymakers at federal and state agencies
- Judges and court staff across the U.S.
- Professors, students, and library staff at every accredited law school in the U.S.
- Attorney and law firm marketing professionals